Loading...
•
Mar 31, 2022
Dynavax Q1 2022 Earnings Report
Reported financial results for the first quarter ended March 31, 2022.
Key Takeaways
Dynavax reported a strong start to 2022 with total revenue of $114.0 million, a 37% increase compared to Q1 2021. The company is on track for a second consecutive year of profitability, driven by growth in HEPLISAV-B vaccine and CpG 1018 adjuvant supply.
Total revenue for the first quarter of 2022 was $114.0 million, up 37% from $83.3 million in Q1 2021.
HEPLISAV-B vaccine net product revenue reached $20.8 million, a 151% increase compared to $8.3 million in Q1 2021.
CpG 1018 adjuvant net product revenue was $91.5 million, up 23% from $74.6 million in Q1 2021.
The company reiterated its guidance for 2022 CpG 1018 revenue, operating expenses, and other costs.
Forward Guidance
Dynavax anticipates 2022 revenues, operating expenses, and other costs to be in the ranges shown below, unchanged from the Company’s previous financial guidance provided on February 28, 2022:
Positive Outlook
- Full-year CpG 1018 adjuvant net product revenues of at least $550 million, with an associated gross margin of approximately 50%
- Research and development expenses to be between approximately $55 - $70 million
- Selling, general and administrative expenses to be between approximately $120 - $140 million
- Interest expense of approximately $7 million
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...